| No. (%) | ||
---|---|---|---|
Clinical characteristics | Infection n = 29 | No infection n = 50 | P |
Cancer stagea | Â | Â | 0.386 |
 Stage III | 4 (14) | 12 (24) |  |
 Stage IV | 24 (86) | 37 (76) |  |
Malignancy type | Â | Â | 0.752 |
 Melanoma | 19 (66) | 36 (72) |  |
 Solid tumor | 10 (34) | 13 (26) |  |
 Hematologic | 0 (0) | 1 (2) |  |
Immune checkpoint inhibitor type | Â | Â | 0.758 |
 Anti-CTLA-4 | 25 (86) | 41 (82) |  |
 Anti-PD-1/L1 | 4 (14) | 9 (18) |  |
Treatment for diarrhea or colitis | Â | Â | 0.483 |
 Steroids alone | 18 (62) | 26 (52) |  |
 Steroids + infliximab | 11 (38) | 24 (48) |  |
Mean length of steroid use (days, SD) | 80.4 (116) | 46.7 (34.5) | 0.063 |
Length of steroid use | Â | Â | 0.160 |
 Short duration (≤ 30 days) | 8 (28) | 22 (44) |  |
 Long duration (> 30 days) | 21 (72) | 28 (56) |  |
Diarrhea grade | Â | Â | 0.353 |
 Grade 1 | 3 (10) | 10 (20) |  |
 Grade 2–4 | 26 (90) | 40 (80) |  |
Colitis grade | Â | Â | 1.000 |
 Grade 1 | 11 (38) | 19 (38) |  |
 Grade 2–3 | 18 (62) | 31 (62) |  |